This article is only available in the PDF format. Download the PDF to view the article, as well as its associated figures and tables.
Dr Yaffee's comments pertaining to "pseudotumors," probably meaning pseudomalignancies, are generally applicable to the concept of pseudomalignancies, and we do not claim to have illusions about understanding any one or all of them. His unfortunate experience with a case of metastasizing fibrosarcoma points out the important fact that dermatologists should have a thorough knowledge of the histopathology and clinical manifestations of these tumors. The diversity of histological diagnoses that were rendered in his case points out the unfamiliarity of many a pathologist with these entities.As Dr Yaffee certainly knows, a fibrosarcoma does not qualify as a pseudomalignancy. Misnomer or not, the fact remains that our statements about atypical fibroxanthoma (AFX) in particular, are substantiated by over 200 cases that are recorded in the literature. As pointed out in our article, two cases metastasized, and close follow-up examinations were recommended in all cases of AFX. In our opinion,
Goette DK. Atypical Fibroxanthoma-Reply. Arch Dermatol. 1977;113(7):986. doi:10.1001/archderm.1977.01640070120033